Zdrowie i gospodarka · 09/04/2014

FDA Releases Draft Guidance on Immunogenicity-Related Considerations for Low Molecular Weight Heparin

The Food and Drug Administration (FDA) has made available a draft guidance document outlining the requirements for providing information on impurities and immunogenicity for low molecular weight heparin products in New Drug Applications (NDAs) and Abbreviated New Drug Applications (ANDAs).